Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.30 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | STK17B | O94768 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624850 | 0.81 | L3MBTL1 (0.33) | WDR5POLBKMT2A | |
| SCHEMBL13624852 | 0.77 | TSHR (0.44) | — | |
| SCHEMBL16978292 | 0.74 | KCNH2 (0.42) | ERN1WDR5CXCL12ARMAOB | |
| SCHEMBL742262 | 0.68 | MAOB (0.61) | CXCL12SLC22A6SLC22A8MEN1RAB9A | |
| SCHEMBL31498354 | 0.65 | MAOB (0.57) | POLBSLC22A6SLC22A8MEN1RAB9A | |
| SCHEMBL28059609 | 0.64 | APP (0.47) | ERN1 | |
| SCHEMBL16978291 | 0.64 | STK17B (0.39) | ERN1CXCL12STK17BMAOB | |
| SCHEMBL31509952 | 0.64 | SLC6A2 (0.35) | — | |
| SCHEMBL13369023 | 0.63 | GAA (0.38) | RAB9A | |
| SCHEMBL13624848 | 0.63 | ENPP2 (0.35) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291924-A1 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | BIPAR SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291924-A1 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | BIPAR SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7538252-B2 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | BIPAR SCIENCES, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538252-B2 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | BIPAR SCIENCES, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080076737-A1 | DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080076737-A1 | DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291924-A1 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | TUBB, TUBA1C, TUBB1 | ERN1 2602/4885WDR5 650/4885CXCL12 4249/4885 |
| US-20080076737-A1 | DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | TUBB, TUBA1C, TUBB1 | ERN1 2602/4885WDR5 650/4885CXCL12 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.